
Qian Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2788689/publications.pdf Version: 2024-02-01



ΟΙΔΝ CHEN

#	Article	IF	CITATIONS
1	Mitochondrial targeted antioxidants, mitoquinone and SKQ1, not vitamin C, mitigate doxorubicin-induced damage in H9c2 myoblast: pretreatment vs. co-treatment. BMC Pharmacology & Toxicology, 2021, 22, 49.	2.4	14
2	The Role of Tetrahydrobiopterin and Dihydrobiopterin in Ischemia/Reperfusion Injury When Given at Reperfusion. Advances in Pharmacological Sciences, 2010, 2010, 1-11.	3.7	12
3	Inhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injury. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1057-1061.	2.2	7
4	TRIACSIN C, A FATTY ACYL COA SYNTHETASE (FACS) INHIBITOR, IMPROVES CARDIAC PERFORMANCE FOLLOWING GLOBAL ISCHEMIA. FASEB Journal, 2012, 26, 1136.18.	0.5	4
5	Mdiviâ€1, a Novel Mitochondrial Fission Inhibitor, Exerts Cardioprotective Effects in Myocardial Ischemia/Reperfusion (MI/R) Injury. FASEB Journal, 2015, 29, 1049.1.	0.5	2
6	Protein Kinase C Epsilon Peptide Inhibitor Exerts Cardioprotective Effects in Myocardial Ischemia/Reperfusion Injury. FASEB Journal, 2017, 31, 846.17.	0.5	2
7	Tetrahydrobiopterin (BH4) attenuates neutrophil adhesion/transmigration in myocardial ischemia/reperfusion injury. FASEB Journal, 2007, 21, A1145.	0.5	1
8	Real time measurement of hydrogen peroxide (H 2 O 2) and nitric oxide (NO) release in the renal vein: The effects of Protein Kinase C beta II inhibitor (PKC β â€) on rat kidneys exposed to extracorporeal shock wave lithotripsy (ESWL). FASEB Journal, 2008, 22, 1160.8.	0.5	1
9	Real time measurement of hydrogen peroxide (H 2 O 2) or nitric oxide (NO) in femoral ischemia/reperfusion (I/R): Effects of protein kinase C (PKC) epsilon activator (ε+) or inhibitor (εâ€) combined with tetrahydrobiopterin (BH 4) or dihydrobiopterin (BH 2). FASEB Journal, 2009, 23, 617.19.	0.5	1
10	Naltrindole Exhibits Robust Cardioprotection in Myocardial Ischemia Reperfusion Injury. FASEB Journal, 2021, 35, .	0.5	0
11	Tetrahydrobiopterin (BH4) exerts cardioprotective effects in ischemia/reperfusion injury when given at reperfusion. FASEB Journal, 2007, 21, A1145.	0.5	0
12	The mechanisms related to the cardioprotective effects of protein kinase C epsilon (PKC εâ€) peptide inhibitor in ischemia/reperfusion (I/R) injury when given at reperfusion. FASEB Journal, 2008, 22, 730.27.	0.5	0
13	Real time measurement of hydrogen peroxide (H 2 O 2)and nitric oxide (NO) release in femoral vein ischemia and reperfusion (I/R): The effects of tetrahydrobiopterin (BH 4)/dihydrobiopterin (BH 2) and the effects of Protein Kinase C (PKC) epsilon activation (ε+)/inhibition (εâ^'). FASEB Journal, 2008, 22, 730.1.	0.5	0
14	The combination of protein kinase C epsilon activator (PKC Îμ +) and tetrahydrobiopterin (BH 4) exerts cardioprotective effects in ischemia/reperfusion injury (I/R) when given during reperfusion. FASEB Journal, 2008, 22, 730.22.	0.5	0
15	The attenuation of leukocyteâ€endothelial interactions by a unique broadâ€spectrum protein kinase C inhibitor (Gö 6983) in rat mesenteric postcapillary venules. FASEB Journal, 2009, 23, 762.7.	0.5	0
16	Protein kinase C beta II inhibitor attenuates leukocyteâ€endothelial interactions during acute endothelial dysfunction. FASEB Journal, 2009, 23, 762.9.	0.5	0
17	Mechanisms related to endothelial nitric oxide synthase (eNOS) uncoupling in myocardial ischemia/reperfusion (MI/R). FASEB Journal, 2009, 23, 793.13.	0.5	0
18	Inhibition of protein kinase C beta II attenuates local hyperglycemiaâ€induced leukocyteâ€endothelial interactions. FASEB Journal, 2010, 24, 590.12.	0.5	0

QIAN CHEN

#	Article	IF	CITATIONS
19	The roles of protein kinase C (PKC) epsilon and tetrahydrobiopterin (BH 4)/dihydrobiopterin (BH 2) related to endothelial nitric oxide synthase (eNOS) coupling/uncoupling in ischemia/reperfusion (I/R). FASEB Journal, 2010, 24, 591.12.	0.5	0
20	The effects of modulating eNOS activity and coupling on leukocyteâ€endothelial interactions in rat mesenteric postcapillary venules. FASEB Journal, 2012, 26, 680.12.	0.5	0
21	Tetrahydrobiopterin (BH4) attenuates extracorporeal shock wave lithrotripsy (ESWL) induced blood nitric oxide (NO) level reduction in the renal vein. FASEB Journal, 2012, 26, 1137.5.	0.5	0
22	Effects of NADPH oxidase inhibitor apocynin on realâ€ŧime blood hydrogen peroxide release in femoral artery/vein ischemia and reperfusion. FASEB Journal, 2012, 26, 678.8.	0.5	0
23	Apocynin exerts cardioprotection in ischemia/reperfusion (I/R) by inhibiting superoxide release from NADPH oxidase. FASEB Journal, 2012, 26, 1136.16.	0.5	0
24	Apocynin exerts doseâ€dependent cardioprotective effects by attenuating reactive oxygen species (ROS) in ischemia/reperfusion (I/R). FASEB Journal, 2013, 27, 1191.1.	0.5	0
25	The Cardioprotective Effects of the Mitochondrial Fission Inhibitor, P110, on Myocardial Ischemia/Reperfusion (MI/R) Injury. FASEB Journal, 2015, 29, 954.7.	0.5	0
26	The Cardioprotective Effects of a NOX1 Inhibitor, ML171, on Myocardial Ischemia/Reperfusion (I/R) injury. FASEB Journal, 2015, 29, 635.3.	0.5	0
27	Effects of NOXâ€1 on Realâ€Time Blood Nitric Oxide and Hydrogen Peroxide in Acute Hyperglycemia. FASEB Journal, 2016, 30, 734.10.	0.5	0
28	Modulation of Nitric Oxide Release in Human Umbilical Vein Endothelial Cells by Myristolatedâ€₽KC Epsilon Activator/Inhibitor Peptides. FASEB Journal, 2018, 32, 902.19.	0.5	0
29	The Role of Autophagy During Myocardial Ischemia/Reperfusion Injury. FASEB Journal, 2018, 32, 717.21.	0.5	0
30	Comparing the Efficacy of Pharmacological Preconditioning with Myristic Acid onjugated, TAT― conjugated and Native Protein Kinase C Epsilon Peptide Activator in Myocardial Ischemia/Reperfusion (MI/R) Models. FASEB Journal, 2018, 32, .	0.5	0
31	Cardioprotective Effects by a Novel Opioid Peptide in Myocardial Ischemia/Reperfusion Injury. FASEB Journal, 2018, 32, 717.23.	0.5	0
32	The Effects of Metformin on Methylglyoxalâ€induced cardiomyocytes cell damage. FASEB Journal, 2018, 32, 719.11.	0.5	0
33	Protein Kinase C Beta II Peptide Inhibitor Elicits Robust Effects on Attenuating Myocardial Ischemia/Reperfusion Injury. FASEB Journal, 2019, 33, 690.6.	0.5	0
34	Protein Kinase C Beta II Peptide Modulation of Superoxide Release in Rat Polymorphonuclear Leukocytes. FASEB Journal, 2019, 33, 836.5.	0.5	0
35	The Effects of Metformin, Aminoguanidine, and Pyridoxamine on Methylglyoxal Induced Cardiac Myocytes Injury. FASEB Journal, 2019, 33, 514.6.	0.5	0
36	Myristoylation of Novel Protein Kinase C Beta II Peptide Inhibitor is Required for the Attenuation of Phorbol 12â€myristate 13â€acetateâ€induced Superoxide Release in Isolated Rat Polymorphonuclear Leukocytes. FASEB Journal, 2020, 34, 1-1.	0.5	0

QIAN CHEN

#	Article	IF	CITATIONS
37	Abstract 445: Myristoylated Protein Kinase C Beta II Peptide Inhibitor Attenuates Hypoxia-Reoxygenation Injury in Human Umbilical Vein Endothelial Cells. Circulation Research, 2020, 127, .	4.5	ο
38	Abstract 447: Myristoylation of Protein Kinase C Beta II Peptide Inhibitor Facilitates Rapid Attenuation of Phorbol 12-myristate 13-acetate in Activated Superoxide Release in Isolated Rat Polymorphonuclear Leukocytes. Circulation Research, 2020, 127, .	4.5	0
39	Abstract P500: Naltrindole And Naltrindole Derivatives Exhibit Potent Cardioprotection In Myocardial Ischemia Reperfusion Injury. Circulation Research, 2021, 129, .	4.5	0
40	Abstract P509: Novel Protein Kinase C Epsilon Inhibitor Attenuates Uncoupled Endothelial Nitric Oxide Synthase And Vascular Endothelial Dysfunction. Circulation Research, 2021, 129, .	4.5	0
41	Preconditioning Using Naltrindole or its Analogues Exerts Robust Infarct‣paring Effects in Rat Myocardial Ischemia/Reperfusion. FASEB Journal, 2022, 36, .	0.5	Ο
42	Myristoylated Protein Kinase C Beta II Inhibitor Attenuates Renal Injury in Mice Subjected to Severe Bilateral Ischemiaâ€Reperfusion. FASEB Journal, 2022, 36, .	0.5	0
43	Myristic Acidâ€Transâ€Activator of Transcription Dual Conjugation Improves Intracellular Delivery of Protein Kinase C Beta II Peptide Inhibitor Cargo in Isolated Rat Polymorphonuclear Leukocytes. FASEB Journal, 2022, 36, .	0.5	Ο
44	Naltrindole Pretreatment Exhibits Robust Cardioprotection in an Acute In Vivo Model of Ischemia/Reperfusion. FASEB Journal, 2022, 36, .	0.5	0